Patent directory · USPTO A61K / A61P
Patents matching “SION”
1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12201639
Aqueous oral pharmaceutical suspension compositions
granted -
US 12188017
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
granted -
US 12188020
Methods for reducing Ataxin-2 expression
granted -
US 12186428
Combination taxoid nanoemulsion with immunotherapy in cancer
granted -
US 12180463
Lactobacillus reuteri
granted -
US 12181555
3-dimensional representations of post-contrast enhanced brain lesions
granted -
US 12171761
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 12168036
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
granted -
US 12162920
Hinge area and use of same in constructing car skeleton
granted -
US 2024390332
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
granted -
US 12151001
Optimized expression cassettes for gene therapy
granted -
US 12150777
Treatment of depression
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12145974
Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12121532
Modified antisense oligomers for exon inclusion in spinal muscular atrophy
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted -
US 12109236
Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
granted